Global and Regional Parkinson's Disease Treatment Market

Parkinson's Disease Treatment Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies), Patient Care Setting (Hospitals, Clinics), Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, Mao Inhibitors, Comt Inhibitors, Anticholinergics, Other Drugs) Players and Region - Global Market Outlook to 2029

Parkinson's Disease Treatment Market by XX Submarkets | Forecast Years 2024-2029 | CAGR: 10.9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Parkinson's Disease Treatment
Parkinson’s disease is a type of chronic and progressive movement disorder that includes malfunction and death of vital nerves cells in the brain, termed as neurons. Some of these dying neurons yield dopamine, a chemical that sends messages to the part of the brain, which controls coordination and movement. As Parkinson’s disease progresses, the amount of dopamine produced in the brain decreases, leaving a person unable to control movement normally. Some of the studies have found that genetic factors, and environmental factors can also be caused of Parkinson’s disease. Environmental factors such as exposure to environmental toxin or injury may possess the risk of Parkinson’s disease. According to National Institute of Environmental Health Sciences, 0.5 million people of the US currently have the disease, and prevalence is rising with the population ages. The major endeavour of the Parkinson’s illness treatment is to offer control on symptoms and signs, for instance, difficulty with walking, shakiness in hands, slowness of movement, and so on.

AttributesDetails
Study Period2018-2029
Base Year2023
UnitValue (USD Billion)
CAGR10.9%


The key manufacturers are targeting the innovations of the services with better quality, and better technical characteristics, and also assist in providing and humanizing the after-sale service to the consumers. The key players are probable to keep a stronghold on the market over the anticipated period. The key players are accepting strategic decisions and are thinking about mergers and acquisitions in order to maintain their presence in the market. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Parkinson's Disease Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GSK (United Kingdom), Merck (United States), Novartis AG (Switzerland), Teva (Israel), Boehringer Ingelheim (Germany), Impax Laboratories (United States), Abbvie (United States), Valeant Pharmaceuticals (Canada), Lundbeck (Denmark) and Sun Pharma (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Wockhardt (India), Acadia (United States), UCB (Belgium) and Dr. Reddy’s (India).

Segmentation Overview
AMA Research has segmented the market of Global Parkinson's Disease Treatment market by and Region.



On the basis of geography, the market of Parkinson's Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Europe region held largest market share in the year 2023. North America, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Parkinson's Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Patient Care Setting, the sub-segment i.e. Hospitals will boost the Parkinson's Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Carbidopa/Levodopa will boost the Parkinson's Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
According to Parkinson.org More than 10 million people a year are living with Parkinson’s disease and Medications of individual costs around 2500 USD a year, and therapeutic surgery costs around 100,000 USD for individual

Market Growth Drivers:
Growth in Aging Population and the Associated Increase in the Prevalence of Parkinson’s disease and Government Funding for Research

Challenges:
Limited Therapeutic Options

Restraints:
Availability of Alternative Treatments

Opportunities:
Patent Expiry of Branded Drugs and Strong Drug Pipeline

Market Leaders and their expansionary development strategies
In December 2023, Pfizer and University of California, San Diego partnerd to advance research on using stem cell therapy for Parkinson's disease, aiming to restore lost dopamine-producing neurons.
In October 2023, First non-invasive ultrasound therapy approved in Europe where ultrasound stimulation device targets specific brain regions, offering a non-surgical option for managing tremor in Parkinson's disease.


Key Target Audience
Parkinson’s disease treatment product manufacturers, Parkinson’s disease treatment dealers and suppliers, Human identification service providers, Parkinson’s disease associations, Academic institutions, Venture capitalists, Consulting firms and Government bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Distribution Channel
  • Hospital Pharmacies
  • Retailer Pharmacies
  • Online Pharmacies

By Patient Care Setting
  • Hospitals
  • Clinics

By Drug Class
  • Carbidopa/Levodopa
  • Dopamine Receptor Agonists
  • Mao Inhibitors
  • Comt Inhibitors
  • Anticholinergics
  • Other Drugs

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growth in Aging Population and the Associated Increase in the Prevalence of Parkinson’s disease
      • 3.2.2. Government Funding for Research
    • 3.3. Market Challenges
      • 3.3.1. Limited Therapeutic Options
    • 3.4. Market Trends
      • 3.4.1. According to Parkinson.org More than 10 million people a year are living with Parkinson’s disease
      • 3.4.2. Medications of individual costs around 2500 USD a year, and therapeutic surgery costs around 100,000 USD for individual
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Parkinson's Disease Treatment, by Distribution Channel, Patient Care Setting, Drug Class and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Parkinson's Disease Treatment (Value)
      • 5.2.1. Global Parkinson's Disease Treatment by: Distribution Channel (Value)
        • 5.2.1.1. Hospital Pharmacies
        • 5.2.1.2. Retailer Pharmacies
        • 5.2.1.3. Online Pharmacies
      • 5.2.2. Global Parkinson's Disease Treatment by: Patient Care Setting (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
      • 5.2.3. Global Parkinson's Disease Treatment by: Drug Class (Value)
        • 5.2.3.1. Carbidopa/Levodopa
        • 5.2.3.2. Dopamine Receptor Agonists
        • 5.2.3.3. Mao Inhibitors
        • 5.2.3.4. Comt Inhibitors
        • 5.2.3.5. Anticholinergics
        • 5.2.3.6. Other Drugs
      • 5.2.4. Global Parkinson's Disease Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Parkinson's Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GSK (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Boehringer Ingelheim (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Impax Laboratories (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abbvie (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Valeant Pharmaceuticals (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lundbeck (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sun Pharma (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Parkinson's Disease Treatment Sale, by Distribution Channel, Patient Care Setting, Drug Class and Region (value) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Parkinson's Disease Treatment (Value)
      • 7.2.1. Global Parkinson's Disease Treatment by: Distribution Channel (Value)
        • 7.2.1.1. Hospital Pharmacies
        • 7.2.1.2. Retailer Pharmacies
        • 7.2.1.3. Online Pharmacies
      • 7.2.2. Global Parkinson's Disease Treatment by: Patient Care Setting (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
      • 7.2.3. Global Parkinson's Disease Treatment by: Drug Class (Value)
        • 7.2.3.1. Carbidopa/Levodopa
        • 7.2.3.2. Dopamine Receptor Agonists
        • 7.2.3.3. Mao Inhibitors
        • 7.2.3.4. Comt Inhibitors
        • 7.2.3.5. Anticholinergics
        • 7.2.3.6. Other Drugs
      • 7.2.4. Global Parkinson's Disease Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Parkinson's Disease Treatment: by Distribution Channel(USD Billion)
  • Table 2. Parkinson's Disease Treatment Hospital Pharmacies , by Region USD Billion (2018-2023)
  • Table 3. Parkinson's Disease Treatment Retailer Pharmacies , by Region USD Billion (2018-2023)
  • Table 4. Parkinson's Disease Treatment Online Pharmacies , by Region USD Billion (2018-2023)
  • Table 5. Parkinson's Disease Treatment: by Patient Care Setting(USD Billion)
  • Table 6. Parkinson's Disease Treatment Hospitals , by Region USD Billion (2018-2023)
  • Table 7. Parkinson's Disease Treatment Clinics , by Region USD Billion (2018-2023)
  • Table 8. Parkinson's Disease Treatment: by Drug Class(USD Billion)
  • Table 9. Parkinson's Disease Treatment Carbidopa/Levodopa , by Region USD Billion (2018-2023)
  • Table 10. Parkinson's Disease Treatment Dopamine Receptor Agonists , by Region USD Billion (2018-2023)
  • Table 11. Parkinson's Disease Treatment Mao Inhibitors , by Region USD Billion (2018-2023)
  • Table 12. Parkinson's Disease Treatment Comt Inhibitors , by Region USD Billion (2018-2023)
  • Table 13. Parkinson's Disease Treatment Anticholinergics , by Region USD Billion (2018-2023)
  • Table 14. Parkinson's Disease Treatment Other Drugs , by Region USD Billion (2018-2023)
  • Table 15. South America Parkinson's Disease Treatment, by Country USD Billion (2018-2023)
  • Table 16. South America Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 17. South America Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 18. South America Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 19. Brazil Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 20. Brazil Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 21. Brazil Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 22. Argentina Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 23. Argentina Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 24. Argentina Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 25. Rest of South America Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 26. Rest of South America Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 27. Rest of South America Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 28. Asia Pacific Parkinson's Disease Treatment, by Country USD Billion (2018-2023)
  • Table 29. Asia Pacific Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 30. Asia Pacific Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 31. Asia Pacific Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 32. China Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 33. China Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 34. China Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 35. Japan Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 36. Japan Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 37. Japan Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 38. India Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 39. India Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 40. India Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 41. South Korea Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 42. South Korea Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 43. South Korea Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 44. Taiwan Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 45. Taiwan Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 46. Taiwan Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 47. Australia Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 48. Australia Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 49. Australia Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 50. Rest of Asia-Pacific Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 51. Rest of Asia-Pacific Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 52. Rest of Asia-Pacific Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 53. Europe Parkinson's Disease Treatment, by Country USD Billion (2018-2023)
  • Table 54. Europe Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 55. Europe Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 56. Europe Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 57. Germany Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 58. Germany Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 59. Germany Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 60. France Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 61. France Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 62. France Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 63. Italy Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 64. Italy Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 65. Italy Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 66. United Kingdom Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 67. United Kingdom Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 68. United Kingdom Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 69. Netherlands Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 70. Netherlands Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 71. Netherlands Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 72. Rest of Europe Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 73. Rest of Europe Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 74. Rest of Europe Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 75. MEA Parkinson's Disease Treatment, by Country USD Billion (2018-2023)
  • Table 76. MEA Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 77. MEA Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 78. MEA Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 79. Middle East Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 80. Middle East Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 81. Middle East Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 82. Africa Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 83. Africa Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 84. Africa Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 85. North America Parkinson's Disease Treatment, by Country USD Billion (2018-2023)
  • Table 86. North America Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 87. North America Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 88. North America Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 89. United States Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 90. United States Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 91. United States Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 92. Canada Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 93. Canada Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 94. Canada Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 95. Mexico Parkinson's Disease Treatment, by Distribution Channel USD Billion (2018-2023)
  • Table 96. Mexico Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2018-2023)
  • Table 97. Mexico Parkinson's Disease Treatment, by Drug Class USD Billion (2018-2023)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Parkinson's Disease Treatment: by Distribution Channel(USD Billion)
  • Table 109. Parkinson's Disease Treatment Hospital Pharmacies , by Region USD Billion (2024-2029)
  • Table 110. Parkinson's Disease Treatment Retailer Pharmacies , by Region USD Billion (2024-2029)
  • Table 111. Parkinson's Disease Treatment Online Pharmacies , by Region USD Billion (2024-2029)
  • Table 112. Parkinson's Disease Treatment: by Patient Care Setting(USD Billion)
  • Table 113. Parkinson's Disease Treatment Hospitals , by Region USD Billion (2024-2029)
  • Table 114. Parkinson's Disease Treatment Clinics , by Region USD Billion (2024-2029)
  • Table 115. Parkinson's Disease Treatment: by Drug Class(USD Billion)
  • Table 116. Parkinson's Disease Treatment Carbidopa/Levodopa , by Region USD Billion (2024-2029)
  • Table 117. Parkinson's Disease Treatment Dopamine Receptor Agonists , by Region USD Billion (2024-2029)
  • Table 118. Parkinson's Disease Treatment Mao Inhibitors , by Region USD Billion (2024-2029)
  • Table 119. Parkinson's Disease Treatment Comt Inhibitors , by Region USD Billion (2024-2029)
  • Table 120. Parkinson's Disease Treatment Anticholinergics , by Region USD Billion (2024-2029)
  • Table 121. Parkinson's Disease Treatment Other Drugs , by Region USD Billion (2024-2029)
  • Table 122. South America Parkinson's Disease Treatment, by Country USD Billion (2024-2029)
  • Table 123. South America Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 124. South America Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 125. South America Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 126. Brazil Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 127. Brazil Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 128. Brazil Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 129. Argentina Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 130. Argentina Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 131. Argentina Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 132. Rest of South America Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 133. Rest of South America Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 134. Rest of South America Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 135. Asia Pacific Parkinson's Disease Treatment, by Country USD Billion (2024-2029)
  • Table 136. Asia Pacific Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 137. Asia Pacific Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 138. Asia Pacific Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 139. China Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 140. China Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 141. China Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 142. Japan Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 143. Japan Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 144. Japan Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 145. India Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 146. India Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 147. India Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 148. South Korea Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 149. South Korea Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 150. South Korea Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 151. Taiwan Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 152. Taiwan Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 153. Taiwan Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 154. Australia Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 155. Australia Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 156. Australia Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 157. Rest of Asia-Pacific Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 158. Rest of Asia-Pacific Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 159. Rest of Asia-Pacific Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 160. Europe Parkinson's Disease Treatment, by Country USD Billion (2024-2029)
  • Table 161. Europe Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 162. Europe Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 163. Europe Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 164. Germany Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 165. Germany Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 166. Germany Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 167. France Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 168. France Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 169. France Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 170. Italy Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 171. Italy Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 172. Italy Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 173. United Kingdom Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 174. United Kingdom Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 175. United Kingdom Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 176. Netherlands Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 177. Netherlands Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 178. Netherlands Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 179. Rest of Europe Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 180. Rest of Europe Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 181. Rest of Europe Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 182. MEA Parkinson's Disease Treatment, by Country USD Billion (2024-2029)
  • Table 183. MEA Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 184. MEA Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 185. MEA Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 186. Middle East Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 187. Middle East Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 188. Middle East Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 189. Africa Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 190. Africa Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 191. Africa Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 192. North America Parkinson's Disease Treatment, by Country USD Billion (2024-2029)
  • Table 193. North America Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 194. North America Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 195. North America Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 196. United States Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 197. United States Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 198. United States Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 199. Canada Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 200. Canada Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 201. Canada Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 202. Mexico Parkinson's Disease Treatment, by Distribution Channel USD Billion (2024-2029)
  • Table 203. Mexico Parkinson's Disease Treatment, by Patient Care Setting USD Billion (2024-2029)
  • Table 204. Mexico Parkinson's Disease Treatment, by Drug Class USD Billion (2024-2029)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Parkinson's Disease Treatment: by Distribution Channel USD Billion (2018-2023)
  • Figure 5. Global Parkinson's Disease Treatment: by Patient Care Setting USD Billion (2018-2023)
  • Figure 6. Global Parkinson's Disease Treatment: by Drug Class USD Billion (2018-2023)
  • Figure 7. South America Parkinson's Disease Treatment Share (%), by Country
  • Figure 8. Asia Pacific Parkinson's Disease Treatment Share (%), by Country
  • Figure 9. Europe Parkinson's Disease Treatment Share (%), by Country
  • Figure 10. MEA Parkinson's Disease Treatment Share (%), by Country
  • Figure 11. North America Parkinson's Disease Treatment Share (%), by Country
  • Figure 12. Global Parkinson's Disease Treatment share by Players 2023 (%)
  • Figure 13. Global Parkinson's Disease Treatment share by Players (Top 3) 2023(%)
  • Figure 14. Global Parkinson's Disease Treatment share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GSK (United Kingdom) Revenue: by Geography 2023
  • Figure 18. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 19. Merck (United States) Revenue: by Geography 2023
  • Figure 20. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 22. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 23. Teva (Israel) Revenue: by Geography 2023
  • Figure 24. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Boehringer Ingelheim (Germany) Revenue: by Geography 2023
  • Figure 26. Impax Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 27. Impax Laboratories (United States) Revenue: by Geography 2023
  • Figure 28. Abbvie (United States) Revenue, Net Income and Gross profit
  • Figure 29. Abbvie (United States) Revenue: by Geography 2023
  • Figure 30. Valeant Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
  • Figure 31. Valeant Pharmaceuticals (Canada) Revenue: by Geography 2023
  • Figure 32. Lundbeck (Denmark) Revenue, Net Income and Gross profit
  • Figure 33. Lundbeck (Denmark) Revenue: by Geography 2023
  • Figure 34. Sun Pharma (India) Revenue, Net Income and Gross profit
  • Figure 35. Sun Pharma (India) Revenue: by Geography 2023
  • Figure 36. Global Parkinson's Disease Treatment: by Distribution Channel USD Billion (2024-2029)
  • Figure 37. Global Parkinson's Disease Treatment: by Patient Care Setting USD Billion (2024-2029)
  • Figure 38. Global Parkinson's Disease Treatment: by Drug Class USD Billion (2024-2029)
  • Figure 39. South America Parkinson's Disease Treatment Share (%), by Country
  • Figure 40. Asia Pacific Parkinson's Disease Treatment Share (%), by Country
  • Figure 41. Europe Parkinson's Disease Treatment Share (%), by Country
  • Figure 42. MEA Parkinson's Disease Treatment Share (%), by Country
  • Figure 43. North America Parkinson's Disease Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GSK (United Kingdom)
  • Merck (United States)
  • Novartis AG (Switzerland)
  • Teva (Israel)
  • Boehringer Ingelheim (Germany)
  • Impax Laboratories (United States)
  • Abbvie (United States)
  • Valeant Pharmaceuticals (Canada)
  • Lundbeck (Denmark)
  • Sun Pharma (India)
Additional players considered in the study are as follows:
Wockhardt (India) , Acadia (United States) , UCB (Belgium) , Dr. Reddy’s (India)
Select User Access Type

Key Highlights of Report


Jan 2024 235 Pages 62 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global and Regional Parkinson's Disease Treatment Market Quantitative research analysis
Global and Regional Parkinson's Disease Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GSK (United Kingdom), Merck (United States), Novartis AG (Switzerland), Teva (Israel), Boehringer Ingelheim (Germany), Impax Laboratories (United States), Abbvie (United States), Valeant Pharmaceuticals (Canada), Lundbeck (Denmark) and Sun Pharma (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"According to Parkinson.org More than 10 million people a year are living with Parkinson’s disease " is seen as one of major influencing trends for Parkinson's Disease Treatment Market during projected period 2023-2029.
The Parkinson's Disease Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.
Analysts at AMA estimates Parkinson's Disease Treatment Market to reach USD5.24 Billion by 2029.

Know More About Global and Regional Parkinson's Disease Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Mantle Cell Lymphoma Treatment Comprehensive Study by Type (Acalabrutinib, JCAR-017, JNJ-64052781, Acalisib, IGN-002, IMGN-529, AFM-11, Others), Application (Hospital, Clinic, Others), Route of Admin...
$ 3650
Non-alcoholic Steatohepatitis Comprehensive Study by Type (Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, Others), Application (Hypertension, Heart Disease, High Blood Lipid, Diabetes, Obesity), En...
$ 3450
Ophthalmology Drugs Comprehensive Study by Type (Lucentis (Ranibizumab), Eylea (Aflibercept), Avastin (Bevacizumab), Restasis (Cyclosporine), Alphagan (Brimonidine Tartrate), Lumigan (Bimatoprost), X...
$ 3750
Hodgkin Lymphoma Treatment Comprehensive Study by Type (Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others), Application (Hospital, Clinic, Research Center), Treatment (Immunotherapy, Ra...
$ 3650
Cervical Cancer Diagnostic Tests Comprehensive Study by Type (Pap Test, HPV Typing Test, Colposcopy, Biopsy, Bimanual Pelvic Examination), Application (Hospitals, Specialty Clinics, Cancer and Radiat...
$ 3450
Overactive Bladder Treatment Comprehensive Study by Type (Self-Care (Absorbent Pads, Scheduled Toileting, Double Voiding, Bladder Training), Therapies (Biofeedback, Kegel Exercise), Medications (Blad...
$ 3750